Macrophage migration inhibitory factor levels in the vitreous of patients with proliferative diabetic retinopathy

被引:28
作者
Mitamura, Y
Takeuchi, S
Matsuda, A
Tagawa, Y
Mizue, Y
Nishihira, J
机构
[1] Toho Univ, Sakura Hosp, Dept Ophthalmol, Sakura, Chiba 2858741, Japan
[2] Hokkaido Univ, Sch Med, Dept Ophthalmol, Sapporo, Hokkaido 060, Japan
[3] Hokkaido Univ, Sch Med, Cent Res Inst, Sapporo, Hokkaido 060, Japan
[4] Sapporo Immunodiagnost Lab, Sapporo, Hokkaido, Japan
关键词
D O I
10.1136/bjo.84.6.636
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Aims-To assess the potential role of macrophage migration inhibitory factor (MIF) in the pathogenesis of proliferative diabetic retinopathy (PDR). Methods-MIF levels were assayed in the vitreous and paired serum samples of 73 consecutive patients with PDR (32 eyes) and macular hole or idiopathic epiretinal membrane (controls, 41 eyes). An enzyme linked immunosorbent assay technique was used to determine the concentrations of MIF. Results-The median vitreous level of MIF was 11.93 ng/ml (range 4.16-103.85) in the patients with PDR, and 1.79 ng/ml (undetectable-8.93) in the controls. Vitreous levels in eyes with PDR were significantly greater than those in the controls (p<0.0001). Vitreous levels were significantly higher than serum levels in eyes with PDR (p=0.0026). MIF levels were significantly higher in the vitreous of PDR patients with severe fibrous proliferation than in those with slight proliferation (p<0.05). Conclusion-The results indicate increased levels of MIF in the vitreous of patients with PDR and a significant association between MIF levels and grades of fibrous proliferation, suggesting the possibility that MIF may play a part in the development of the proliferative phase of PDR.
引用
收藏
页码:636 / 639
页数:4
相关论文
共 18 条
[1]   Monocyte chemotactic protein-1 in proliferative vitreoretinal disorders [J].
AbuElAsrar, AM ;
VanDamme, J ;
Put, W ;
Veckeneer, M ;
Dralands, L ;
Billiau, A ;
Missotten, L .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1997, 123 (05) :599-606
[2]   An essential regulatory role for macrophage migration inhibitory factor in T-cell activation [J].
Bacher, M ;
Metz, CN ;
Calandra, T ;
Mayer, K ;
Chesney, J ;
Lohoff, M ;
Gemsa, D ;
Donnelly, T ;
Bucala, R .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (15) :7849-7854
[3]   IMMUNOHISTOLOGIC STUDY OF EPIRETINAL MEMBRANES IN PROLIFERATIVE VITREORETINOPATHY [J].
BAUDOUIN, C ;
FREDJREYGROBELLET, D ;
GORDON, WC ;
BAUDOUIN, F ;
PEYMAN, G ;
LAPALUS, P ;
GASTAUD, P ;
BAZAN, NG .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1990, 110 (06) :593-598
[4]   MECHANISM OF A REACTION IN VITRO ASSOCIATED WITH DELAYED-TYPE HYPERSENSITIVITY [J].
BLOOM, BR ;
BENNETT, B .
SCIENCE, 1966, 153 (3731) :80-&
[5]   MACROPHAGE IS AN IMPORTANT AND PREVIOUSLY UNRECOGNIZED SOURCE OF MACROPHAGE-MIGRATION INHIBITORY FACTOR [J].
CALANDRA, T ;
BERNHAGEN, J ;
MITCHELL, RA ;
BUCALA, R .
JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 179 (06) :1895-1902
[6]  
Capeans C, 1998, RETINA-J RET VIT DIS, V18, P546
[7]   CYTOKINES IN PROLIFERATIVE DIABETIC-RETINOPATHY AND PROLIFERATIVE VITREORETINOPATHY [J].
ELNER, SG ;
ELNER, VM ;
JAFFE, GJ ;
STUART, A ;
KUNKEL, SL ;
STRIETER, RM .
CURRENT EYE RESEARCH, 1995, 14 (11) :1045-1053
[8]   MACROPHAGES IN PROLIFERATIVE VITREORETINOPATHY AND PROLIFERATIVE DIABETIC-RETINOPATHY - DIFFERENTIATION OF SUBPOPULATIONS [J].
ESSER, P ;
HEIMANN, K ;
WIEDEMANN, P .
BRITISH JOURNAL OF OPHTHALMOLOGY, 1993, 77 (11) :731-733
[9]   Transforming growth factor β2 in the vitreous in proliferative diabetic retinopathy [J].
Hirase, K ;
Ikeda, T ;
Sotozono, C ;
Nishida, K ;
Sawa, H ;
Kinoshita, S .
ARCHIVES OF OPHTHALMOLOGY, 1998, 116 (06) :738-741
[10]   FIBROVASCULAR PROLIFERATION AND RETINAL-DETACHMENT AFTER INTRAVITREAL INJECTION OF ACTIVATED MACROPHAGES IN THE RABBIT EYE [J].
HUI, YN ;
GOODNIGHT, R ;
SORGENTE, N ;
RYAN, SJ .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1989, 108 (02) :176-184